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Abstract: 
Autosomal recessive COX4I1 deficiency has been previously reported in a single individual who 
presented with short stature, poor weight gain, dysmorphic features, and features of Fanconi 
anemia caused by a homozygous pathogenic variant in COX4I1. COX4I1 encodes the subunit 4, 
isoform 1 of cytochrome c oxidase. Cytochrome c oxidase is a respiratory chain enzyme that 
plays an important role in mitochondrial electron transport and reduces molecular oxygen to 
water leading to the formation of ATP. Defective production of cytochrome c oxidase leads to 
variable phenotypic spectrum ranging from isolated myopathy to Leigh syndrome. Here, we 
describe siblings, born to consanguineous parents, who presented with encephalopathy, 
developmental regression, hypotonia, pathognomonic brain imaging findings resembling Leigh  
syndrome and a novel homozygous variant on COX4AI1, expanding the known clinical 
phenotype associated with pathogenic variants in COX4I1.  
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1. INTRODUCTION 
Biallelic variants in COX4I1 (OMIM: 123864) have been previously described in a 
patient who presented with short stature, poor weight gain, dysmorphic features and features of 
Fanconi anemia (Abu-libdeh et al., 2017). COX4I1, located at 16q24.1, encodes the subunit IV 
isoform 1, the principal isoform for COX-IV subunit of cytochrome c oxidase (COX) or 
Complex IV in human beings and other vertebrates. COX plays an important role in oxidative 
phosphorylation by transferring electrons from cytochrome c to molecular oxygen and 
contributes to a proton electrochemical gradient across the inner mitochondrial membrane 
necessary for ATP formation (Li et al., 2006). Complex IV consists of 14 different subunits, 
including three encoded by mitochondrial DNA (COX subunits I-III) that form an important 
catalytic core of the enzyme. The remaining 11 subunits encoded by nuclear DNA (COX 
subunits IV, Va, Vb, VIa, VIb, VIc, VIIa, VIIb, VIIc, VIII and NDUFA4) are found to be tightly 
bound to subunits I-III (Sinkler et al., 2017). COX IV exists in two isoforms in humans and other 
mammals, COX subunit IV isoform 1 (COXIV- I1) and COX subunit IV isoform 2 (COX IV-
I2). COX4I1 is ubiquitously expressed in mammals (Sinkler et al., 2017). Mitochondrial diseases 
resulting in COX deficiency (OMIM: 220110) present with marked clinical heterogeneity 
ranging from fatal neonatal lactic acidosis to adult myopathy.  Here, we describe a novel 
COX4I1 variant in two siblings who present with developmental regression, seizures and 
pathognomonic changes in brain imaging resembling a Leigh syndrome phenotype.  
2. CLINICAL REPORT 
2.1 Patient 1 is a three-year-old male who was born to consanguineous Iraqi parents at 37 weeks 
of gestation via C-section. His birth weight was 3.316 kilograms (kg). He had normal growth and 
development throughout the first eight months of life. Developmental regression of motor skills 
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became evident at eight months of age when he stopped crawling and standing up with support. 
An extensive biochemical work up, including acylcarnitine profile, plasma amino acids, urine 
organic acids analyses, and creatine kinase (CK), provided  unremarkable results. Lactate was 
slightly elevated at 3.0 mmol/L (Reference range: 0.2-2.0 mmol/L). Brain MRI showed mild to 
moderate generalized cerebral/cerebellar atrophy and evidence of bilateral hypertrophic olivary 
degeneration with conspicuous non-enhancing lesions along the medullary/pyramid and subtle 
signal changes along the bilateral basal ganglia and cerebellar fossa (Figure 1a). These findings 
were concerning for mitochondrial encephalopathy, which prompted a referral to Genetics Clinic 
at Texas Children’s Hospital.  
Upon evaluation at Genetics Clinic at 13 months of age, he had further regression of his 
motor skills.  He was unable to sit without support and did not have head control. He had 
profound hypotonia and required gastrostomy tube placement for feedings.  Family history was 
significant for a nine-year-old male sibling with a similar clinical presentation.  At the time of 
the initial visit, his weight was 8.82 kg (13th percentile), his height was 74 cm (8th percentile) and 
his head circumference was 44.5 cm (7th percentile). Physical examination did not show any 
dysmorphic features except bilateral hypoplasia of the distal phalanges of the 2nd-5th toes (Figure 
1b). He also had axial and appendicular hypotonia and patellar hyperreflexia.  He developed 
seizures at two years of age, described as epileptic spasms without hypsarrhythmia, as captured 
on electroencephalogram (EEG). Currently, his antiepileptic treatment includes zonisamide and 
levetiracetam.  Untargeted metabolomics analysis of his plasma and CSF demonstrated elevated 
lactate and fumarate (Table 1). His chromosomal microarray (oligonucleotide + SNP) did not 
show any copy number variants but detected long contiguous stretches with absence of 
heterozygosity (AOH) encompassing 137 Mb in total consistent with the history of parental 
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consanguinity.  Exome sequencing revealed a homozygous variant in COX4I1 (Table 1). 
Coenzyme Q10 (Ubiquinol) therapy was initiated at 8 mg/kg/day following confirmation of 
molecular diagnosis. Four months after initiation of therapy with Coenzyme Q10, parents 
reported improvement in head control and tone. 
2.2   Patient 2 is the older sibling of Patient 1 and is an 11 years old male. He was born full term 
in Iraq. He met all developmental milestones at appropriate ages until 11 months of life. 
Regression of motor skills was noted around 11 months of age when he started to have frequent 
falls and was unable to stand up. Infantile spasms associated with hypsarrhythmia on EEG 
started at 12 months for which he was treated with ACTH. His seizures were also treated with 
topiramate and valproic acid.  Motor regression continued through the 1st year of life.  
Clonazepam was initiated to treat myoclonic jerks. He had a normal comprehensive work up 
including CK, plasma amino acids, urine organic acid analysis, carbohydrate deficient 
transferrin, lactate and pyruvate. MRI of the brain showed gliosis of bilateral basal ganglia, 
thalami, cerebellum and periventricular white matter with diffuse cerebral and cerebellar volume 
loss, and congenital hypoplasia of the inferior vermis (Figure 1c). His electromyogram (EMG) 
was normal. He had multiple genetic tests, including SCN1A deletion-duplication and sequencing 
and comprehensive epilepsy next generation sequencing panel, which were normal. A 
chromosomal microarray was done, which showed multiple areas of AOH consistent with the 
history of parental consanguinity.  
Upon confirmation of the sibling’s diagnosis through exome sequencing, Patient 2 had 
known familial mutation testing for COX4I1, which identified homozygosity for the same variant 
(Table 1). At the time of initial evaluation at the Genetics Clinic, he was 14 years of age.  He had 
profound hypotonia with poor head control, inability to sit unsupported and was wheelchair 
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bound. Like his brother, he also required gastrostomy tube for feedings. He had failure to thrive 
as evidenced by weight, height, and head circumference at 2nd, < 1st , < 2nd percentiles, 
respectively. He did not have any dysmorphic features. He had notable hypotonia with strength 
greater in left side than the right.  EEG evolved into multifocal spikes with the pattern of 
epileptic encephalopathy. Skeletal muscle analysis after muscle biopsy at eight years of age 
revealed mild type II myofiber atrophy. A mitochondrial respiratory chain enzyme analysis on 
the muscle biopsy specimen showed that complex IV activity was reduced (Supplementary Table 
1). Coenzyme Q10 therapy (Ubiquinol) was initiated at 8.5 mg/kg/day following confirmation of 
molecular diagnosis. Parents reported improvement in visual focus four months after initiation of 
Coenzyme Q10 therapy. 
3. RESULTS 
   A homozygous c.454C>A (p.P152T) variant in COX4I1 was detected by trio exome 
sequencing in Patient 1 and confirmed by familial mutation testing in Patient 2. This amino acid 
is highly conserved across multiple vertebrate species from zebrafish to humans, and this variant 
is absent in public databases such as ExAC or gnomAD (Lek et al., 2016). In silico analyses for 
conservation suggests that this variant is evolutionarily conserved and constrained (phastCons 
score=1, phyloP=7.461). Furthermore, Ensembl predictors (that combine multiple in silico 
algorithms as features to reach a prediction) support the variant to be likely damaging to the 
COX4I1 protein product (REVEL score: 0.839 (threshold >0.75 implies damaging). The 
identified homozygous COX4I1 variant resides in one of the AOH blocks spanning 
approximately 5.3 Mb located on chromosome 16q23.1–16q24.1. Both Patient 1 and Patient 2 
had normal chromosomal breakage studies.  
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Untargeted metabolomics profiling on plasma and CSF in Patient 1 showed elevated 
fumarate (Z-score 2.9) and lactate (Z-score 3.4; Table 1). The mitochondrial respiratory chain 
enzyme analysis done on muscle biopsy specimen of Patient 2 showed that cytochrome c oxidase 
activity was reduced to 16% residual activity compared to control values, meeting a major 
modified Walker criterion (Supplementary Table 1). 
4. DISCUSSION 
Only recently a human autosomal recessive disorder linked to COX4I1 has been 
identified. Abu-Libdeh et al described a novel mitochondrial disease associated with a 
homozygous variant in COX4I1 in a 3.5-year-old female who presented with Fanconi anemia, 
short stature, poor weight gain, mild dysmorphic features, and normal brain MRI without 
features indicative of mitochondrial disease (Abu-libdeh et al., 2017). The siblings presented 
herein share some phenotypic features including short stature, failure to thrive and microcephaly 
(Table 1) in the presence of a novel homozygous variant (p.P152T) in COX4I1.  While both 
siblings did not have evidence of Fanconi anemia as mentioned previously, they had additional 
manifestations including developmental regression, intellectual disability, seizures and 
pathognomonic changes in brain imaging resembling Leigh syndrome that were not present in 
the first reported case. These additional features suggest a phenotypic expansion of COX4I1 
deficiency. To our knowledge, this is the second clinical report involving a variant in COX4I1 
and the first report describing a Leigh-like syndrome association with COX4I1 deficiency.   
The most common presentation of mitochondrial disease in the pediatric population is in 
the form of Leigh syndrome (subacute necrotizing encephalomyelopathy) (Lake et al., 2015). 
The clinical features, including but not limited to developmental delay and regression, dystonia, 
ataxia and ophthalmoplegia, are often seen in conjunction with imaging findings such as bilateral 
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symmetric T2 hyperintensitities in basal ganglia and/or brain stem with MR spectroscopy 
revealing elevated brain lactate levels (Bonfante et al., 2016; Cavanagh & Harding, 1994; 
Rahman et al., 1996; Sofou et al., 2014). 
Even though both siblings described here did not have hematological features and 
abnormal chromosome breakage studies consistent with Fanconi anemia, other hematological 
disorders such as sideroblastic anemia has been previously well described in multisystemic 
mitochondrial disorders such as Pearson syndrome, MLASA syndrome (mitochondrial 
myopathy, lactic acidosis, and SA) and complex I deficiency  associated with a hemizygous 
change in NDUFB11 (Falcon & Howard, 2017; Lichtenstein et al., 2016; Rileyet al., 2010; 
Tesarova et al., 2019). However, it was not until recently that defective oxidative metabolism 
and mitochondrial localization along with spontaneous mitochondrial fragmentation have been 
described in Fanconi anemia cells (Bottega et al., 2018; Cappelli et al., 2017; Pagano et al., 
2014). Imbalance of NAD+/NADH in COX deficiency has been postulated as the underlying 
mechanism of DNA instability and increased double-stranded DNA breaks (Douiev & Saada, 
2018). Further follow-up in our patients is required in order to establish whether hematological 
features are a consistent finding that would be associated with COX4I1 deficiency. 
The first variant described by Abu-Libdeh et al in COX4I1 was found to be in a 
conserved residue in the transmembrane helix domain that interacts with COX I and COX II 
leading to decreased mRNA expression and COX activity in the patient’s fibroblasts (Abu-libdeh 
et al., 2017).  Similarly, the variant observed in the siblings presented herein is conserved across 
many species, and ETC analysis on the muscle biopsy specimen from patient 2 revealed 
reduction in COX activity, further supporting the pathogenicity of this variant in our patients.  
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   Interestingly, untargeted metabolomics profiling (Kennedy et al., 2017; Miller et al., 
2015) performed on patient 1 revealed elevated lactate and fumarate, which indicate perturbation 
in energy metabolism secondary to mitochondrial dysfunction further providing functional 
evidence for the pathogenicity of the variant identified in COX4I1. Evidence of mitochondrial 
dysfunction by the use of untargeted metabolomic analysis in CSF and plasma may provide 
functional validation for variants of unknown significance observed in nuclear genes associated 
with mitochondrial disease, providing semi-quantitative values for TCA cycle intermediates and 
altered lipid metabolism as a consequence of abnormal mitochondrial function (Esterhuizen et 
al., 2017; Shayota et al., 2019; Tam et al., 2019).  
Treatment with Coenzyme Q10 in mitochondrial disorders is well established in 
Coenzyme Q10 deficiency (Duncan et al., 2009; Rötig et al., 2000). In disorders where 
mitochondrial respiratory chain is affected, Coenzyme Q10, in addition to restoring electron flow 
in the mitochondrial respiratory chain, also acts as an antioxidant and helps reduce the oxidative 
stress and has been recommended despite lack of proven efficacy (Hargreaves, 2014; Parikh et 
al., 2014). Given these facts, Coenzyme Q10 was started in both patients herein presented. The 
treatment has provided minor clinical improvements four months following initiation of therapy.  
We hypothesize that therapeutic trial with Coenzyme Q10 in patients with COX4I1 deficiency 
may help stabilize the course of the disease.     
In summary, the clinical features of short stature, failure to thrive, microcephaly, 
developmental regression, intellectual disability, seizures and pathognomonic finding of Leigh-
like syndrome on brain imaging along with untargeted metabolomics findings and the reduced 
COX activity proven by muscle biopsy provide functional evidence for the pathogenicity of the 
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variants described here and further suggest expansion of the clinical phenotype linked to 
autosomal recessive COX4I1 deficiency.  
 
 
ACKNOWLEDGMENTS  
The authors would like to thank the patients, their families and all physicians involved in their 
care.   
INFORMED CONSENT 
Genetic analysis was performed after obtaining a written informed consent from both parents. 
Consent to publish clinical data of the patients was obtained from both parents of the minors. 
CONFLICT OF INTEREST:  
Fernando Scaglia receives research support from NIH, BioElectron Technologies, and Stealth 
Therapeutics; and is an investigator in the North American Mitochondrial Disease Consortium. 
Nishitha R Pillai is supported by Sanofi Genzyme ACMGF Next Generation Training Award.   
REFERENCES 
Abu-libdeh, B., Douiev, L., Amro, S., Shahrour, M., Ta-shma, A., Miller, C., … Saada, A. 
(2017). Mutation in the COX4I1 gene is associated with short stature , poor weight gain and 
increased chromosomal breaks , simulating Fanconi anemia. European Journal of Human 
Genetics, 25(10), 1142–1146. https://doi.org/10.1038/ejhg.2017.112 
Bonfante, E., Koenig, M. K., Adejumo, R. B., Perinjelil, V., & Riascos, R. F. (2016). The 
neuroimaging of Leigh syndrome : case series and review of the literature, 46(4) 443–451. 
https://doi.org/10.1007/s00247-015-3523-5 
Bottega, R., Nicchia, E., Cappelli, E., Ravera, S., Rocco, D. De, Faleschini, M., … Savoia, A. 
(2018). Hypomorphic FANCA mutations correlate with mild mitochondrial and clinical 
phenotype in Fanconi anemia Correspondence : Hematologica, 103(3), 417–426. 
https://doi.org/10.3324/haematol.2017.176131 
 11 
Cappelli, E., Cuccarolo, P., Stroppiana, G., Miano, M., Bottega, R., Cossu, V., … Ravera, S. 
(2017). Defects in mitochondrial energetic function compels Fanconi Anaemia cells to 
glycolytic metabolism. BBA - Molecular Basis of Disease, 1863(6), 1214–1221. 
https://doi.org/10.1016/j.bbadis.2017.03.008 
Cavanagh, J. B., & Harding, B. N. (1994). Pathogenic factors underlying the lesions in leigh’s 
disease: Tissue responses to cellular energy deprivation and their clinico-pathological 
consequences. Brain, 117 ( Pt 6):1357-76 . https://doi.org/10.1093/brain/117.6.1357 
Douiev, L., & Saada, A. (2018). The pathomechanism of cytochrome c oxidase deficiency 
includes nuclear DNA damage. Biochimica et Biophysica Acta - Bioenergetics, 
1859(9):893-900. https://doi.org/10.1016/j.bbabio.2018.06.004 
Duncan, A. J., Bitner-glindzicz, M., Meunier, B., Costello, H., Hargreaves, I. P., Hirano, M., … 
Rahman, S. (2009). A Nonsense Mutation in COQ9 Causes Autosomal-Recessive Neonatal-
Onset Primary Coenzyme Q 10 Deficiency : A Potentially Treatable Form of Mitochondrial 
Disease. The American Journal of Human Genetics, 84(5):558-66. 
https://doi.org/10.1016/j.ajhg.2009.03.018 
Esterhuizen, K., Westhuizen, F. H. Van Der, & Louw, R. (2017). Mitochondrion Metabolomics 
of mitochondrial disease. Mitochondrion, 35(August 2016), 97–110. 
https://doi.org/10.1016/j.mito.2017.05.012 
Falcon CP, H. T. (2017). An infant with Pearson syndrome: a rare cause of congenital 
sideroblastic anemia and bone marrow failure, Blood;129(19):2710 129. 
https://doi.org/10.1182/blood-2017-02-766881 
Hargreaves, I. P. (2014). Coenzyme Q 10 as a therapy for mitochondrial disease. International 
Journal of Biochemistry and Cell Biology, 49, 105–111. 
https://doi.org/10.1016/j.biocel.2014.01.020 
Kennedy, A. D., Pappan, K., Donti, T. R., Evans, A. M., Wulff, J. E., Miller, L. A. D., … Elsea, 
S. H. (2017). Elucidation of the Complex Metabolic Profile of Cerebrospinal Fluid Using an 
Untargeted Biochemical Profiling Assay. Mol Genet Metab., 121(2), 83–90. 
https://doi.org/10.1016/j.ymgme.2017.04.005.Elucidation 
Lake, N. J., Bird, M. J., Isohanni, P., & Paetau, A. (2015). Leigh Syndrome : Neuropathology 
and Pathogenesis, J Neuropathol Exp Neurol.;74(6):482-92. 
https://doi.org/10.1097/NEN.0000000000000195 
Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., … 
MacArthur, D. G. (2016). Analysis of protein-coding genetic variation in 60,706 humans. 
Nature, 536, 285–291. https://doi.org/10.1038/nature19057 
Lichtenstein, D. A., Crispin, A. W., Sendamarai, A. K., Campagna, D. R., Schmitz-abe, K., 
Sousa, C. M., … Fleming, M. D. (2016). A recurring mutation in the respiratory complex 1 
protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood, 
128(15), 1913–1918. https://doi.org/10.1182/blood-2016-05-719062.The 
Miller, M. J., Kennedy, A. D., Eckhart, A. D., Burrage, L. C., Wulff, J. E., Miller, L. A. D., … 
Elsea, S. H. (2015). Untargeted metabolomic analysis for the clinical screening of inborn 
 12 
errors of metabolism. Journal of Inherited Metabolic Disease, 38, 1029–1039. 
https://doi.org/10.1007/s10545-016-9944-y 
Pagano, G., Shyamsunder, P., Verma, R. S., & Lyakhovich, A. (2014). Damaged mitochondria in 
Fanconi anemia – an isolated event or a general phenomenon, Oncoscience. 2014;1(4):287-
95. https://doi.org/10.18632/oncoscience.29 
Parikh, S., Goldstein, A., Kay, M., Scaglia, F., Enns, G. M., Anselm, I., … Wolfe, L. A. (2014). 
Mitochondrion Practice patterns of mitochondrial disease physicians in North America . 
Part 1 : Diagnostic and clinical challenges ☆ Russell Saneto f , for the Mitochondrial 
Medicine Society Clinical Directors Working Group , Other members of the MMS Clin. 
MITOCH, 14(6), 26–33. https://doi.org/10.1016/j.mito.2013.07.116 
Rahman S, Blok RB, Dahl H-HM, Dank DM, Kirby DM, Chow CW, Christodoulou J, T. D. L. 
(1996). Leigh Syndrome : Clinical Features and Biochemical and and DNA Abnormalities, 
Ann Neurol. 1996, 39(3):343-51. https://doi.org/10.1002/ana.410390311 
Riley LG, Cooper S, Hickey P, Rudinger-Thirion J, McKenzie M, Compton A, Lim SC, 
Thorburn D, Ryan MT, Giegé R, Bahlo M, C. J. (2010). Mutation of the Mitochondrial 
Tyrosyl-tRNA Synthetase Gene , YARS2 , Causes Myopathy , Lactic Acidosis , and 
Sideroblastic Anemia — MLASA Syndrome. The American Journal of Human Genetics 87, 
52–59. https://doi.org/10.1016/j.ajhg.2010.06.001 
Rötig, A., Appelkvist, E., Geromel, V., Chretien, D., Kadhom, N., Edery, P., … Rustin, P. 
(2000). Quinone-responsive multiple respiratory-chain dysfunction due to widespread 
coenzyme Q 10 deficiency. Lancet, 356, 391–395. https://doi.org/10.1016/S0140-
6736(00)02531-9 
Shayota, B. J., Soler-Alfonso, C., Bekheirnia, M. R., Mizerik, E., Boyer, S. W., Xiao, R., … 
Scaglia, F. (2019). Case report and novel treatment of an autosomal recessive Leigh 
syndrome caused by short-chain enoyl-CoA hydratase deficiency. American Journal of 
Medical Genetics, Part A, 179A, 803–807. https://doi.org/10.1002/ajmg.a.61074 
Sinkler, C. A., Kalpage, H., Shay, J., Lee, I., Malek, M. H., Grossman, L. I., & Hüttemann, M. 
(2017). Tissue- and Condition-Specific Isoforms of Mammalian Cytochrome c Oxidase 
Subunits : From Function to Human Disease, 2017. https://doi.org/10.1155/2017/1534056 
Sofou, K., Coo, I. F. M. De, Isohanni, P., Ostergaard, E., Naess, K., Meirleir, L. De, … Darin, N. 
(2014). A multicenter study on Leigh syndrome : disease course and predictors of survival, 
Orphanet J Rare Dis. 2014;9:52. https://doi.org/10.1186/1750-1172-9-52 
Tam, A., Aldhaheri, N. S., Elizabeth, M., John, T., Fernandez, L. A., Alessandro, A. M. D., … 
Fernando, H. E. (2019). Improved clinical outcome following liver transplant in patients 
with ethylmalonic encephalopathy, (February), 1–5. https://doi.org/10.1002/ajmg.a.61104 
Tesarova, M., Stranecky, V., Galoova, N., Vondrackova, A., Berankova, K., Honzik, T., … 
Vodickova, E. (2019). Sideroblastic anemia associated with multisystem mitochondrial 
disorders, 66(4):e27591. https://doi.org/10.1002/pbc.27591 
Youfen Li, Jeong-Soon Park, Jian-Hong Deng,  and Y. B. (2006). Cytochrome c Oxidase 
Subunit IV is Essential for Assembly and Respiratory Function of the Enzyme Complex, 
 13 
38, 283–291. https://doi.org/10.1042/BJ20090214 
 
Clinical features Abu-Libdeh et al., 2017 Our cases 
Sibling 1 Sibling2 
COX4I1 genotype Homozygous 
c.412G>A (p.Glu138Lys) 
hg19 (GRCh27) 
Homozygous  
c.454C>A (p.P152T)  
hg19 (GRCh37) 
Homozygous  
c.454C>A (p.P152T) 
hg19 (GRCh37) 
Short stature + + + 
Weight <3rd centile + + + 
Microcephaly + + + 
Dysmorphic features Prominent nasal bridge, fifth 
finger clinodactyly, frontal 
bossing 
- - 
Developmental 
regression 
- + + 
Seizure - + + 
MRI brain Normal Hypertrophic olivary 
degeneration, cerebellar 
volume loss 
T2 prolongation in basal 
ganglia and thalami, 
volume loss of thalami 
Elevated serum lactate - + - 
Chromosome breakage 
studies 
+ - - 
Metabolomic profile 
Plasma 
N/A Fumarate + 2.9 
Lactate +1.14 
 
N/A 
Metabolomic profile 
CSF 
N/A Lactate + 3.4 N/A 
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 Table 1. Comparison of the clinical and laboratory features of COX4I1 deficiency. 
Comparison between the first case presented by Abu-Libdeh et al., 2017 and our patients. 
Clinical, molecular, brain imaging and laboratory features are presented.  In addition, 
metabolomic data for Case 1 is also presented showing elevated fumarate and lactate in plasma 
and CSF samples respectively. Numerical values represent Z-scores of different metabolic 
analyte levels. Metabolomic analysis was performed at Baylor Genetics 
(www.BaylorGenetics.com) (Miller et al., 2015; Kennedy et al 2017). 
 
Figure legends 
Figure 1. a: Diffuse cerebellar volume loss and hypertrophic olivary degeneration in Case 1. b: 
Distal toe hypoplasia in Case 1. c: Abnormal T2 prolongation in basal ganglia and thalami with 
volume loss of bilateral caudal heads and thalamus in Case 2. 
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